Clinical research
The FDA has approved two of Phathom Pharmaceuticals’ products for bacterial illnesses in adults: Voquezna Triple Pak and Voquezna Dual Pak.
Compass and AstraZeneca have both provided updates to their clinical therapeutic programs focused on biliary tract cancers.
Novartis’ Kisqali (ribociclib) plus the chemotherapy drug fulvestrant provided some post-menopausal breast cancer patients’ survival benefit of more than five-and-a-half years of life.
Dianthus Therapeutics, Enavate Sciences and CytoTronics were all launched with this recent wave of investor funding. For that and more, continue reading.
Moderna held its 2022 Q1 earnings call this morning announcing $6.1 billion in revenue and robust plans to roll out COVID-19 boosters this fall.
Connect Biopharma Phase II trial on a potential drug for adults with moderate-to-severe ulcerative colitis may have failed to meet its primary endpoint, but the company isn’t giving up yet.
The FDA accepted Bayer’s supplemental New Drug Application for its proposed oral treatment for metastatic hormone-sensitive prostate cancer.
Horizon Therapeutics announced its Phase II dazodalibep (HZN-4920) clinical trial has met its primary endpoint. Dazodalibep is a treatment for patients with Rheumatoid Arthritis (RA).
GPH101 is an investigational next-generation gene-edited autologous hematopoietic stem cell (HSC) therapy.
Denali Therapeutics, Inc. has announced that dosing has begun for participants of a Phase II clinical trial that intends to evaluate the potential of SAR443820 (DNL788) in patients with amyotrophic lateral sclerosis (ALS).
PRESS RELEASES